TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~All patients age \> =18 who have been diagnosed with Multiple Myeloma and are scheduled for autologous peripheral blood hematopoietic stem cell transplant (AHSCT) will be screened for eligibility.~Patients must fulfill all of the following inclusion criteria to be eligible for this study:~1. Diagnosis of Multiple Myeloma~2. Age \>=18 and no more than 70 years.~3. Able to understand and sign a consent form.~4. Can collect peripheral blood stem cells with a CD34+ cell dose of at least 5.0 x 106/kg. The CD34 molecule is a Cluster of Differentiation molecule present on hematopoietic stem cells.~5. Conditioning regimen to be high dose Melphalan at a dose of 200mg/m2.~6. Karnofsky Performance Score (KPS) \>60 or ECOG (Eastern Cooperative Oncology Group) performance status \<=2~7. Kidney function:Creatinine \<2.0 mg/dl or creatinine clearance \>50 ml/min~8. Heart function: Ejection fraction \>45%~9. Liver function tests :Serum bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST) less than 3 X upper limit of normal~10. Lung function tests: Forced Vital Capacity (FVC), Forced Expiratory Volume in One Second (FEV1) or Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) \>45% predicted~Exclusion Criteria:~1. Age \<18 years or \> 70 years~2. Previous exposure to denileukin diftitox.~3. Patients with documented uncontrolled central nervous system (CNS) disease.~4. Previous AHSCT.~5. Significant organ dysfunction deemed to be inappropriate for autologous transplantation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Denileukin Diftitox (Ontak) (Type: EXPERIMENTAL): Denileukin Diftitox (Ontak) administered Post Autologous Transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Impact of Non-slip Socks on Motor Recovery in the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient in Geriatric acute care or Post-Emergency Medicine,~* Patient 75 years and older,~* Patient requiring physiotherapy,~* Patient with a minimum of 7 days of physical therapy~* Patient arrived with unsuitable footwear (assessment at the discretion of the clinician: no back support, unsuitable size, etc.) or without footwear,~* Patient able to walk at least 10 m with or without technical assistance,~* Patient who has given oral consent~* Patient with social security coverage.~Exclusion Criteria:~* Inability to understand or perform study-specific clinical tests~* Known cognitive impairment, disease or condition that compromises comprehension of information or informed consent by the patient~* Blind patient~* Patient under guardianship or curatorship~* Patient participating in an interventional clinical research protocol that may alter the assessments of this protocol.~* Patient previously included in the Charm study~* Patient with an identified risk of being unable to wear socks or to walk barefoot within the next 7 days (need for compression stockings or socks, wound, excessive edema, orthostatic hypotension, other)

- Gender: ALL
- Minimum Age: 75 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- usual care with bare feet (Type: NO_INTERVENTION): patients will be treated barefoot during their stay
- specific care with anti-slip socks (Type: EXPERIMENTAL): Patients in this group will wear non-slip socks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* female or male of 50 to 85 years old with a care giver~* Mini Mental Status (MMS) test between 16 to 26 inclusive~* Clinical Dementia Rating (CDR) test inferior or equal to 1~* National Institute of Neurological and Communicative Disorders and Stroke / Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) test positive for an Alzheimer's disease~* Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV) test positive for dementia~Exclusion Criteria:~* patient already treated by medicines which could interfere with the study~* low level of vitamin B12 and folate which are considered as clinically relevant~* clinically relevant pathologies (eg: pulmonary illness, cardiovascular illness; evolutive cancer, neurological illness, blood illness....)

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- EGb 761® (Tanakan®) (Type: EXPERIMENTAL): EGb 761® (Tanakan®)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Abiraterone-Rechallenge Study for CRPC Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Written prostate cancer.~2. Adult patients with histological or cytological diagnosis of adenocarcinoma of the prostate.~3. Men with castration-resistant metastatic decline maintained for at least 3 weeks as per PCWG2 criteria).~4. Confirmed biochemical response to prior abiraterone acetate (≥50% PSA Informed Consent (including consent for biomarker studies including the fresh tumour biopsies)~5. Progressive disease according to PCWG2 criteria during prior therapy with standard dose of abiraterone acetate (confirmed increase of PSA ≥25% over nadir) or soft-tissue or bone progression. Patients that have stopped abiraterone acetate for reasons other than progression are not eligible.~6. Documented progression of disease by any of the criteria listed here:~   * PSA~  * Soft tissue~  * Bone scan all as per PCWG2 criteria~7. Patients may have received treatment with docetaxel, enzalutamide or radium-223~8. PSA of ≥10ug/l~9. ECOG performance status 0 - 2~10. At least 3 months (90 days) since stop of prior abiraterone acetate.~Exclusion Criteria:~1. Major surgery within 28 days weeks prior to start of treatment~2. Prior treatment with cabazitaxel or the CYP-17 inhibitor TAK-700/orteronel~3. Any concurrent treatment or prior treatment with an investigational drug within 28 days prior to start of treatment.~4. Known brain or leptomeningeal disease~5. Concurrent use of steroids other than prednisone \>10mg/d~6. Inadequate bone marrow and organ function as evidenced by:~   Platelet count \<75 x 10 G/L ASAT and/or ALAT ≥ 2.5 x ULN Total bilirubin ≥ 1.5 x ULN (≥ 2.0 x ULN for patients with Gilbert's disease) Hypokalaemia despite adequate supplementation Creatinine Clearance \<30ml/min~7. Uncontrolled hypertension or cardiac failure or LVEF \<50%~creatinine clearance is to be calculated by using the formula of Cockcroft-Gault in appendix 4 of the protocol

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Abiraterone (Type: EXPERIMENTAL): Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have precursor-B lymphoblastic leukemia or lymphoma.~2. Patients must be untreated or have had only one prior chemotherapy regimen for ALL or LL . Previously treated patients will be analyzed separately.~3. Age between 12 to 30 years old~4. Patients with central nervous system (CNS) disease or testicular disease are eligible.~5. Intrathecal therapy with cytarabine is allowed prior to registration for patient convenience. This is usually done at the time of the diagnostic bone marrow or venous line placement to avoid a second lumbar puncture. Systemic chemotherapy must begin within 72 hours of the first intrathecal treatment.~6. Signed informed consent prior to the start of systemic therapy. In the event of enrollment of a minor patient, an attempt to obtain assent from the patient must be documented, and parental consent must be signed.~7. Echocardiogram should be done within 7 days of starting therapy if there are cardiac risk factors (e.g., history of hypertension or of myocardial infarction)~8. Creatinine should be \< 3 mg/dL bilirubin \< 3 mg/dl unless due to disease~9. Zubrod Performance status of \<3~10. Patients who received steroids more than 72 hours prior to study enrollment are eligible but will be analyzed separately.~11. Lymphoblasts may have any positive expression of cluster of differentiation antigen 20 (CD20) for ofatumumab administration.~Exclusion Criteria:~1. Age less than twelve years of age or greater than 30 years.~2. More than one prior treatment regimen for ALL or LL.~3. The patient is pregnant or unwilling to practice appropriate birth control.~4. Presence of the Philadelphia chromosome t(9;22)~5. Laboratory or clinical evidence of active infectious hepatitis.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Augmented BFM Therapy + Ofatumumab or Rituximab (Type: EXPERIMENTAL): Participants receive the study drugs in Induction, Consolidation, and Maintenance Courses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tacks Versus Glue for Mesh Fixation in Laparoscopic Ventral Hernia Repair Treating Defects Between 2 and 5 cm Width

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient with ventral hernia (primary or incisional) with a defect size between 2 and 5 cm and eligible for laparoscopic repair.~2. Patients with ASA grade I to III.~3. Patient is at least 18 years old.~4. Patient must sign and date the informed consent form prior to treatment.~Exclusion Criteria:~1. Patient with a recurrence of a previously treated ventral hernia repaired with mesh. Recurrences are only allowed to be included after former primary (suture) repair or retromuscular/onlay mesh repair.~2. Patient is treated by open surgery.~3. Patient has more than one defect. Treatment of Swiss-cheese defects (multiple small defects) is allowed if all defects can be treated with one mesh. Total width cannot exceed 5 cm.~4. Patient with a complex hernia, likely not eligible for laparoscopic repair. Complexity is determined by the investigator (adhesions, small bowel resection, etc).~5. Patient with a life expectancy of less than 2 years.~6. Patient is suspected of being unable to comply with the study protocol.~7. Patient with severe chronic obstructive pulmonary disease.~8. Patient with ASA IV or V.~9. Patient is pregnant.~10. Patient needs acute surgery.~11. Patient is scheduled for surgery within 6 weeks after the index-procedure.~12. Patient has fibromyalgia.~13. Patient with depression as shown in patient medical record.~14. Patient is enrolled in another study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liquiband Fix8 glue mesh fixation (Type: ACTIVE_COMPARATOR): None
- Mesh fixation with absorbable tacks (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study With Aminophylline to Attenuate of the Side Effects of Regadenoson

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients referred to undergo a clinically-indicated regadenoson-stress myocardial perfusion imaging at Rush University Medical Center~Exclusion Criteria:~* Patient refusal to participate~* Known allergic reaction to aminophylline.~* Pre-existing headache or acute/subacute GI illness with symptoms of diarrhea, abdominal discomfort, nausea or vomiting.~* Any contraindication to aminophylline: hypotension, unstable cardiac arrhythmias and acute coronary symptoms.~* Uncontrolled seizure disorder defined as more than 2 seizure episodes in the past 12 months or any seizure in the past week.~* Pregnant or breast-feeding women.~* Patients receiving anti-platelet agent dipyridamole (Persantine® or Aggrenox®).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aminophylline (Type: EXPERIMENTAL): 75 mg of intravenous aminophylline.
- Placebo (Type: PLACEBO_COMPARATOR): Matching normal saline placebo (sterile salt water).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Parental Irradiation of Ukrainian Cleanup Workers and Evacuees and Germline Mutations in Their Offspring (Trio Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: FAMILY_BASED
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~* all parent-offspring trios/quartets selected from the group of approximately 450 trios with offspring born 42 or more weeks after the last significant parental Chernobyl-related exposure. ---The offspring can be of either sex~* Must be an adult~(age (Bullet) 18 years at interview);~* If more than one child is born to a given set of parents, the first and last such eligible siblings will be selected for participation, in the interests of maximizing the variation of time from last exposure to conception, also to maximize the signal (by including offspring closest in time to the exposure, with less likelihood of removal of damaged sperm/oocytes, and by including offspring furthest in time from the exposure, with less likelihood of direct exposure of the child, and maximizing cumulative parental preconception gonadal dose).~* Twins will be especially informative given the comparable exposures in utero and in early life. A high proportion of the trios/quartets currently reside in Kyiv. The majority of these trios/quartets have undergone regular medical examinations as a result of follow-up by the CER. Most of them are expected to be alive.~EXCLUSION CRITERIA:~* Those who cannot be located~* Those with offspring born within 42 weeks of the last significant Chernobyl-related exposure~* Those parents or offspring found to have cancer~* Those who refuse to participate in the study, or who do not provide informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Trio Cohort (Type: None): families were from each of 5 exposure categories: A-father exposed, mother unexposed; B-mother exposed, father unexposed; C-both parents exposed; D-neither exposed; E-high dose emergency workers).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Does in Vivo Culture of Pre-cleavage Stage Embryo Reduce the Incidence of Aneuploidy?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed Consent by the subject and her partner~* Women, aged between 18 and 38 years (up to 38th birthday)~* ≤ 2 previous stimulation cycles~* Routinely measured hormonal levels within normal range (i.e. FSH, LH, E2, PRL)~* No uterine or ovarian anatomical abnormalities and/or alterations that would compromise device delivery or function in the uterus as demonstrated by ultrasound and trial insertion~* 19 ≤ BMI ≤ 29 kg/m2~Exclusion Criteria:~* History of previous moderate or severe ovarian hyperstimulation syndrome (OHSS)~* Severe endometriosis~* Any active infection that would contraindicate ART, at the discretion of the investigator~* Severe male factor in the partner (cryptozoospermia or non-obstructive azoospermia)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: t

Study Arms:
- sibling oocytes in vivo (Type: EXPERIMENTAL): randomized oocytes assigned to in vivo culture
- sibling oocyte in vitro (Type: ACTIVE_COMPARATOR): randomized oocytes assigned to in vitro culture

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pre- Versus Postoperative Accelerated Partial Breast Irradiation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients ≥ 51 years~* clinical stage tumor-1-2 (≤ 3 cm)~* cN0~* Grade I or grade II (biopsy)~* Histologically proven invasive ductal adenocarcinoma~* Unifocal lesions on mammogram and MRI (small satellite lesions adjacent to the tumor are accepted as long as it is suitable for local excision to be determined by the participating centre)~* World Health Organization performance status ≤ 2~* Life expectancy ≥ 5 years~* Written informed consent~Exclusion Criteria:~* Distant metastases~* Lobular invasive carcinomas~* Pure Ductal Carcinoma in situ (DCIS) without invasive tumor~* Grade III in biopsy~* Triple negative tumors~* HER2neu positive tumors~* Lymphvascular invasion in biopsy~* TNM pathologic stage N1-3~* pN+ (micro- or macrometastases)~* Multicentric / multifocal disease on mammogram or MRI~* Diffuse calcifications on mammogram (Birads 3, 4 or 5)~* Prior treatment for the protocol tumor (no surgery, no neoadjuvant chemotherapy or neoadjuvant hormonal therapy, no previous radiotherapy)~* Previous contralateral breast cancer~* Other neoplasms in the last 5 years with the exception of:~* Basal cell carcinoma of the skin~* Adequately treated carcinoma in situ of the cervix~* Planned oncoplastic resection with tissue displacement~* No social security affiliation/health insurance~* Participation in another clinical trial that interferes with the locoregional treatment of this protocol~* It is expected that dosimetric constraints cannot be met, ie, lung/heart constraints or if the ratio PTV/ipsilateral breast \>30%

- Gender: FEMALE
- Minimum Age: 51 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- radiotherapy in arm 1 (Type: EXPERIMENTAL): pre-operative accelerated partial breast irradiation
- radiotherapy in arm 2 (Type: ACTIVE_COMPARATOR): post-operative accelerated partial breast irradiation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of a Non-Invasive Hypoglycemia Detector in a Glycogen Storage Disease Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed and clinically treated at the University of Florida with any of the glycogen storage diseases I, III, VI, IX, 0 will be asked to participate in this study.~Exclusion Criteria:~* Patients not clinically treated at the University of Florida.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- GSD 1 (Type: None): These will be subjects with GSD I. The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
- GSD 0, III, VI, or IX (Type: None): These will be subjects with GSD 0, III, VI, or IX. The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy